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To the Editor: The article by Edwards et al. (1) 
contained several errors regarding testing, results, and 
interpretation of results. The authors incorrectly de-
scribed the testing performed for the cord blood samples. 
The American Red Cross (ARC) National Testing Labo-
ratory (NTL) (identified as the “American Red Cross 
National Donor Testing Laboratory” in the article) has 
never performed indirect hemagglutination assay testing, 
a method not licensed by the Food and Drug Adminis-
tration (FDA) for detection of antibodies to Trypanoso-
ma cruzi. In fact, the laboratory used a combination of 
testing algorithms during 2007–2014, the period of the 
study, involving 2 different FDA-licensed screening tests 
and a combination of research and licensed supplemen-
tal tests. Each algorithm had varying positive predictive 
values, ranging from <10% to >50%. The laboratory 
Given the paucity of literature data regarding malaria 
prevalence in internationally adopted children, testing by 
PCR, microscopy, or both, followed by treatment of infect-
ed children, would be preferable to the empiric treatment, 
considering the costs and possible adverse effects of anti-
marial drugs. Moreover, the preferable screening strategy is 
not apparent. We did not observe any discrepancy between 
microscopy and PCR results; however, a higher sensitivity 
by PCR has been reported (4,5). In contrast, some experts 
prefer testing by microscopy examination because PCR 
techniques are not sufficiently standardized or validated to 
be used for routine clinical diagnosis (2).
In our dataset, malaria prevalence was substantially 
higher than that previously reported (4). This finding may 
be due to the particular situation of these children and to or-
phanage conditions (i.e., lack of mosquito nets). Moreover, 
it should be noted that, to date, 3 countries— DRC, Nigeria, 
and India—account for 40% of all estimated malaria cases 
in the world (6). Also, a high prevalence of asymptomatic 
malaria in DRC has been reported, in ≈15% of children (7,8).
Our results should be interpreted with caution, given the 
small dataset, but they should alert pediatricians regarding the 
importance of assessing malaria risk in children who have 
been adopted internationally. The degree of malaria endemic-
ity in the child’s area of origin may be considered in the deci-
sion to screen asymptomatic children adopted in non–malar-
ia-endemic countries. In particular, children who come from 
areas of high malaria endemicity, such as DRC, deserve a 
careful screening, even in the absence of any sign or symptom.
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algorithm from January 2007 to the end of August 2011 
included the FDA-licensed Ortho T. cruzi enzyme immu-
noassay (EIA) (Ortho-Clinical Diagnostics, Inc., Raritan, 
NJ, USA), followed by a research radioimmunoprecipita-
tion assay (RIPA) for supplemental testing of all repeat 
reactive donations.
On September 1, 2011, the laboratory began using the 
FDA-licensed PRISM Chagas chemiluminescent immu-
noassay (Abbott Laboratories, Abbott Park, IL, USA) for 
donor screening, followed by a combination of RIPA and 
the Ortho EIA for supplemental testing. On July 30, 2012, 
the laboratory switched from the RIPA to the FDA-licensed 
Abbott enzyme strip assay (ESA) (Abbott Laboratories) for 
supplemental testing, maintaining concurrent testing with 
the Ortho EIA (2). The ARC NTL notified all customers of 
changes in laboratory testing algorithms.
The results reported in the article do not match those 
recorded at the ARC NTL. The authors describe 25 samples 
that tested reactive by indirect hemagglutination and that 
19 of those were positive by supplemental RIPA testing. In 
addition to the incorrect tests described, reported results do 
not correspond to laboratory records. Reviewing the ARC 
NTL testing results for the Carolinas Cord Blood Bank fa-
cility codes, we found that 34 unique samples tested re-
peat reactive from October 9, 2007, through October 13, 
2014. Of these 34 samples, 11 were positive on supplemen-
tal RIPA testing and none were ESA positive; testing with 
RIPA or ESA was dependent on the algorithm in place at 
the time. Of the 11 samples that were reactive in screening 
tests and showed positive results in supplemental tests, 2 
positives were identified from October–November 2007, 1 
from November 2008, 5 from June 2009–January 2010, 2 
from May–June 2010, and 1 from 2012 (which does not 
correspond to the data in the figure or patterns described in 
the discussion). An additional 4 screening test repeat reac-
tive donations were tested during 2015–2016, with 1 ESA 
positive but Ortho EIA nonreactive.
Test results of submissions from other facility codes for 
Duke University were reviewed to see whether any positive 
samples were submitted from a different North Carolina lab-
oratory; we found 10 additional screening test repeat reac-
tive donations, but none had positive results by supplemen-
tal testing. We do not know whether testing of cord blood 
samples was performed by another laboratory; only the ARC 
NTL was described in the methods of this study.
Much of the interpretation of results was misleading. 
The authors considered any screening test positive result as 
being sufficient for confirmation of infection. To be mean-
ingful, all samples with reactive results should be tested 
further, and only those with reactive or positive results by 
at least 2 different tests considered for any investigation 
of epidemiologic trends. Furthermore, a single serologic 
screening test reactive result confirmed as positive, though 
useful for blood donor management, does not define a con-
firmed diagnosis of Chagas disease (3).
The authors’ use of the term incidence does not agree 
with the epidemiologic definition of that term. The au-
thors state, “The incidence of confirmed Chagas disease 
among mothers who donated their neonate’s cord blood 
varied over time,” “The incidence of Chagas disease var-
ied over time,” and “A strength of this study is its large 
sample size, particularly because the incidence of this 
disease is low.” However, no incident T. cruzi infections 
were identified by their study. No evidence of acute infec-
tion was presented. All mothers who donated cord blood 
were chronically infected; the testing of their samples re-
vealed the prevalence of positive results among the sam-
ples tested in a given period (had the numbers used been 
accurate, which they were not). This distinction is key 
because acute infections are more likely to be transmit-
ted through blood transfusion and patients’ infections are 
more likely to be successfully cured by antitrypanosomal 
treatment during the acute phase of infection, before de-
velopment of cardiac manifestations.
Preventing and controlling congenital Chagas disease is 
a serious public health issue; the screening of mothers at risk 
for transmitting T. cruzi infection to their babies is consid-
ered key to accomplishing these factors. The evidence base 
to support screening recommendations must be high-quality 
and accurate. Other studies have emphasized this risk in the 
US population, particularly in Latin American immigrant 
mothers (4), but further evidence is needed to guide policy 
recommendations. The report of Edwards et al. (1) could be 
a contribution to this needed evidence base, but only if re-
ported data are accurate and appropriately interpreted.
References
  1. Edwards JM, Gilner JB, Hernandez J, Kurtzberg J, Heine RP.  
Chagas disease screening in maternal donors of publicly 
banked umbilical cord blood, United States. Emerg Infect Dis. 
2016;22:1468–70. http://dx.doi.org/10.3201/eid2208.151622
  2. US Food and Drug Administration. Guidance for industry: use of 
serological tests to reduce the risk of transmission of Trypanosoma 
cruzi infection in whole blood and blood components intended  




  3. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, 
Dantas RO, et al. Evaluation and treatment of Chagas disease in 
the United States: a systematic review. JAMA. 2007;298:2171–81. 
http://dx.doi.org/10.1001/jama.298.18.2171
  4. Edwards MS, Rench MA, Todd CW, Czaicki N, Steurer FJ, Bern C, 
et al. Perinatal screening for Chagas disease in southern Texas.  
J Pediatric Infect Dis Soc. 2015;4:67–70. http://dx.doi.org/10.1093/
jpids/pit056
Address for correspondence: Susan P. Montgomery, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, Mailstop A06, Atlanta, 
GA 30329-4027; email: smontgomery@cdc.gov
